Molecular Partners Ag Stock Buy Hold or Sell Recommendation
| MOLN Stock | USD 3.60 0.05 1.37% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Molecular Partners AG is 'Strong Sell'. The recommendation algorithm takes into account all of Molecular Partners' available fundamental, technical, and predictive indicators you will find on this site.
Check out Molecular Partners Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. In addition, we conduct extensive research on individual companies such as Molecular and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Molecular Partners AG. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as various price indices.
Molecular | Build AI portfolio with Molecular Stock |
Execute Molecular Partners Buy or Sell Advice
The Molecular recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Molecular Partners AG. Macroaxis does not own or have any residual interests in Molecular Partners AG or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Molecular Partners' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Weakest | Details | |
Volatility | Unstable | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Barely shadows the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Molecular Partners Trading Alerts and Improvement Suggestions
| Molecular Partners generated a negative expected return over the last 90 days | |
| Molecular Partners has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 4.97 M. Net Loss for the year was (54.04 M) with loss before overhead, payroll, taxes, and interest of (43.09 M). | |
| Molecular Partners AG currently holds about 267.13 M in cash with (59.25 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.22, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Latest headline from news.google.com: What catalysts could drive Molecular Partners AG Depositary Receipt stock higher in 2025 - AI Powered Signals For Consistent Profits - jammulinksnews.com |
Molecular Partners Returns Distribution Density
The distribution of Molecular Partners' historical returns is an attempt to chart the uncertainty of Molecular Partners' future price movements. The chart of the probability distribution of Molecular Partners daily returns describes the distribution of returns around its average expected value. We use Molecular Partners AG price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Molecular Partners returns is essential to provide solid investment advice for Molecular Partners.
| Mean Return | -0.03 | Value At Risk | -6.38 | Potential Upside | 6.74 | Standard Deviation | 3.78 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Molecular Partners historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Molecular Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument, such as Molecular Partners, soars without any apparent reason. This usually happens because many institutional investors are aggressively trading Molecular Partners AG back and forth among themselves. Companies that invest excess capital in these types of assets may also be included in this term and can influence corporate governance by exercising voting rights in their investments.
| Shares | Suvretta Capital Management, Llc | 2025-03-31 | 2.2 M | Bvf Inc | 2025-03-31 | 1.4 M | Ubs Group Ag | 2025-03-31 | 6.4 K | Morgan Stanley - Brokerage Accounts | 2025-03-31 | 367 | Rhumbline Advisers | 2025-03-31 | 269 | Bank Of America Corp | 2025-03-31 | 157 |
Molecular Partners Cash Flow Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change In Cash | 58.0M | (61.9M) | 16.1M | (20.6M) | (3.4M) | (3.6M) | |
| Free Cash Flow | (30.7M) | (92.3M) | 117.1M | (59.8M) | (60.0M) | (57.0M) | |
| Depreciation | 2.9M | 2.6M | 2.4M | 2.4M | 2.4M | 1.9M | |
| Other Non Cash Items | 5.5M | 848K | (753K) | 1.4M | (7.9M) | (8.3M) | |
| Capital Expenditures | 1.7M | 1.3M | 1.4M | 575K | 723K | 896.0K | |
| Net Income | (62.8M) | (63.8M) | 117.9M | (62.0M) | (54.0M) | (51.3M) | |
| End Period Cash Flow | 133.7M | 71.8M | 87.9M | 67.3M | 63.9M | 90.7M | |
| Investments | (20.6M) | (21M) | (101.1M) | 61.1M | 40.5M | 42.5M | |
| Change To Netincome | 2.4M | 8.4M | 4.9M | 4.3M | 5.0M | 5.2M |
Molecular Partners Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Molecular Partners or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Molecular Partners' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Molecular stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.16 | |
β | Beta against Dow Jones | 1.01 | |
σ | Overall volatility | 3.67 | |
Ir | Information ratio | -0.04 |
Molecular Partners Volatility Alert
Molecular Partners AG exhibits very low volatility with skewness of -0.17 and kurtosis of 0.81. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Molecular Partners' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Molecular Partners' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Molecular Partners Fundamentals Vs Peers
Comparing Molecular Partners' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Molecular Partners' direct or indirect competition across all of the common fundamentals between Molecular Partners and the related equities. This way, we can detect undervalued stocks with similar characteristics as Molecular Partners or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Molecular Partners' fundamental indicators could also be used in its relative valuation, which is a method of valuing Molecular Partners by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Molecular Partners to competition |
| Fundamentals | Molecular Partners | Peer Average |
| Return On Equity | -0.4 | -0.31 |
| Return On Asset | -0.24 | -0.14 |
| Operating Margin | (27.55) % | (5.51) % |
| Current Valuation | (23.7 M) | 16.62 B |
| Shares Outstanding | 36.87 M | 571.82 M |
| Shares Owned By Institutions | 9.72 % | 39.21 % |
| Number Of Shares Shorted | 32.48 K | 4.71 M |
| Price To Earning | 1.85 X | 28.72 X |
| Price To Book | 0.83 X | 9.51 X |
| Price To Sales | 61.12 X | 11.42 X |
| Revenue | 4.97 M | 9.43 B |
| Gross Profit | (43.09 M) | 27.38 B |
| EBITDA | (51.65 M) | 3.9 B |
| Net Income | (54.04 M) | 570.98 M |
| Cash And Equivalents | 267.13 M | 2.7 B |
| Cash Per Share | 8.22 X | 5.01 X |
| Total Debt | 2.44 M | 5.32 B |
| Debt To Equity | 0.02 % | 48.70 % |
| Current Ratio | 14.37 X | 2.16 X |
| Book Value Per Share | 3.84 X | 1.93 K |
| Cash Flow From Operations | (59.25 M) | 971.22 M |
| Short Ratio | 17.80 X | 4.00 X |
| Earnings Per Share | (2.16) X | 3.12 X |
| Target Price | 10.68 | |
| Number Of Employees | 158 | 18.84 K |
| Beta | 0.55 | -0.15 |
| Market Capitalization | 136.41 M | 19.03 B |
| Total Asset | 158.53 M | 29.47 B |
| Retained Earnings | (246.29 M) | 9.33 B |
| Working Capital | 143.5 M | 1.48 B |
| Net Asset | 158.53 M |
Molecular Partners Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Molecular . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Molecular Partners Buy or Sell Advice
When is the right time to buy or sell Molecular Partners AG? Buying financial instruments such as Molecular Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Molecular Partners in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Target Outcome ETFs Thematic Idea Now
Target Outcome ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Target Outcome ETFs theme has 87 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Target Outcome ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Molecular Partners Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Molecular Partners. If investors know Molecular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Molecular Partners listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.16) | Revenue Per Share | Quarterly Revenue Growth (1.00) | Return On Assets | Return On Equity |
The market value of Molecular Partners is measured differently than its book value, which is the value of Molecular that is recorded on the company's balance sheet. Investors also form their own opinion of Molecular Partners' value that differs from its market value or its book value, called intrinsic value, which is Molecular Partners' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Molecular Partners' market value can be influenced by many factors that don't directly affect Molecular Partners' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Molecular Partners' value and its price as these two are different measures arrived at by different means. Investors typically determine if Molecular Partners is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Molecular Partners' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.